116 related articles for article (PubMed ID: 25778496)
21. Extracorporeal photopheresis in combination with bexarotene in the treatment of mycosis fungoides and Sézary syndrome.
Tsirigotis P; Pappa V; Papageorgiou S; Kapsimali V; Giannopoulou V; Kaitsa I; Girkas K; Papageorgiou E; Stavrianeas N; Economopoulos T; Dervenoulas J
Br J Dermatol; 2007 Jun; 156(6):1379-81. PubMed ID: 17459033
[No Abstract] [Full Text] [Related]
22. Treatment of mycosis fungoides with bexarotene and psoralen plus ultraviolet A.
Coors EA; Von den Driesch P
Br J Dermatol; 2005 Jun; 152(6):1379-81. PubMed ID: 15949024
[No Abstract] [Full Text] [Related]
23. Evaluation of quantitative measurement of thyroglobulin mRNA in the follow-up of differentiated thyroid cancer.
Denizot A; Delfino C; Dutour-Meyer A; Fina F; Ouafik L
Thyroid; 2003 Sep; 13(9):867-72. PubMed ID: 14588101
[TBL] [Abstract][Full Text] [Related]
24. Effects of short-term metformin therapy associated with levothyroxine dose decrement on TSH and thyroid hormone levels in patients with thyroid cancer.
Mousavi Z; Dourandish L; Rokni H; Sadeghi R; Rasoul Zakavi S
Minerva Endocrinol; 2014 Mar; 39(1):59-65. PubMed ID: 24513605
[TBL] [Abstract][Full Text] [Related]
25. The optimal use of bexarotene in cutaneous T-cell lymphoma.
Gniadecki R; Assaf C; Bagot M; Dummer R; Duvic M; Knobler R; Ranki A; Schwandt P; Whittaker S
Br J Dermatol; 2007 Sep; 157(3):433-40. PubMed ID: 17553039
[TBL] [Abstract][Full Text] [Related]
26. Treatment of mycosis fungoides with oral bexarotene combined with PUVA.
Stern DK; Lebwohl M
J Drugs Dermatol; 2002 Sep; 1(2):134-6. PubMed ID: 12847736
[TBL] [Abstract][Full Text] [Related]
27. High prevalence of mTOR complex activity can be targeted using Torin2 in papillary thyroid carcinoma.
Ahmed M; Hussain AR; Bavi P; Ahmed SO; Al Sobhi SS; Al-Dayel F; Uddin S; Al-Kuraya KS
Carcinogenesis; 2014 Jul; 35(7):1564-72. PubMed ID: 24583924
[TBL] [Abstract][Full Text] [Related]
28. Evolution of clinical and molecular responses to bexarotene treatment in cutaneous T-cell lymphoma.
Ballanger F; Nguyen JM; Khammari A; Dréno B
Dermatology; 2010; 220(4):370-5. PubMed ID: 20484880
[TBL] [Abstract][Full Text] [Related]
29. Follow-up of low-risk differentiated thyroid cancer patients who underwent radioiodine ablation of postsurgical thyroid remnants after either recombinant human thyrotropin or thyroid hormone withdrawal.
Elisei R; Schlumberger M; Driedger A; Reiners C; Kloos RT; Sherman SI; Haugen B; Corone C; Molinaro E; Grasso L; Leboulleux S; Rachinsky I; Luster M; Lassmann M; Busaidy NL; Wahl RL; Pacini F; Cho SY; Magner J; Pinchera A; Ladenson PW
J Clin Endocrinol Metab; 2009 Nov; 94(11):4171-9. PubMed ID: 19850694
[TBL] [Abstract][Full Text] [Related]
30. Successful treatment of a folliculotropic mycosis fungoides with bexarotene and PUVA.
Krönke A; Schlaak M; Arin M; Mauch C; Kurschat P
Eur J Dermatol; 2012; 22(2):259-60. PubMed ID: 22240623
[No Abstract] [Full Text] [Related]
31. [Hormonal therapy in differentiated carcinoma of the thyroid gland].
Francia G; Davì MV; Petroziello A; Sussi PL
Chir Ital; 1994; 46(4):56-8. PubMed ID: 7882445
[TBL] [Abstract][Full Text] [Related]
32. [Randomized controlled trial of hydrochlorothiazide in augmenting the dose of 131I absorbed by thyroid remnant].
Ding H; Kuang AR; Guan CT
Sichuan Da Xue Xue Bao Yi Xue Ban; 2004 Jul; 35(4):546-8. PubMed ID: 15291124
[TBL] [Abstract][Full Text] [Related]
33. [Advances in molecular targeted therapy of thyroid carcinoma].
Feng H; Cheng X; Zeng F
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2015 Dec; 29(24):2188-90. PubMed ID: 27093829
[TBL] [Abstract][Full Text] [Related]
34. Lack of apoptosis of Sézary cells in the circulation following oral bexarotene therapy.
Brennand S; Sutton VR; Biagi J; Trapani JA; Westerman D; McCormack CJ; Seymour JF; Kennedy G; Prince HM
Br J Dermatol; 2005 Jun; 152(6):1199-205. PubMed ID: 15948982
[TBL] [Abstract][Full Text] [Related]
35. Bexarotene increases uptake of radioiodide in metastases of differentiated thyroid carcinoma.
Liu YY; Stokkel MP; Pereira AM; Corssmit EP; Morreau HA; Romijn JA; Smit JW
Eur J Endocrinol; 2006 Apr; 154(4):525-31. PubMed ID: 16556714
[TBL] [Abstract][Full Text] [Related]
36. Melatonin enhanced bexarotene efficacy in experimental mammary carcinogenesis.
Orendas P; Kubatka P; Kajo K; Stollarova N; Kassayova M; Bojkova B; Pec M; Nosal V; Kiskova T; Zihlavnikova K; Karsnakova R
Neoplasma; 2012; 59(4):469-74. PubMed ID: 22489703
[TBL] [Abstract][Full Text] [Related]
37. Ablation of thyroid residues with 30 mCi (131)I: a comparison in thyroid cancer patients prepared with recombinant human TSH or thyroid hormone withdrawal.
Pacini F; Molinaro E; Castagna MG; Lippi F; Ceccarelli C; Agate L; Elisei R; Pinchera A
J Clin Endocrinol Metab; 2002 Sep; 87(9):4063-8. PubMed ID: 12213846
[TBL] [Abstract][Full Text] [Related]
38. Bexarotene via CBP/p300 induces suppression of NF-κB-dependent cell growth and invasion in thyroid cancer.
Cras A; Politis B; Balitrand N; Darsin-Bettinger D; Boelle PY; Cassinat B; Toubert ME; Chomienne C
Clin Cancer Res; 2012 Jan; 18(2):442-53. PubMed ID: 22142826
[TBL] [Abstract][Full Text] [Related]
39. Serum thyroglobulin measurements with a high sensitivity enzyme-linked immunosorbent assay: is there a clinical benefit in patients with differentiated thyroid carcinoma?
Zöphel K; Wunderlich G; Smith BR
Thyroid; 2003 Sep; 13(9):861-5. PubMed ID: 14588100
[TBL] [Abstract][Full Text] [Related]
40. "High-dose" radioiodine therapy in advanced differentiated thyroid carcinoma.
Menzel C; Grünwald F; Schomburg A; Palmedo H; Bender H; Späth G; Biersack HJ
J Nucl Med; 1996 Sep; 37(9):1496-503. PubMed ID: 8790201
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]